Sir,
A 60-year-old hypertensive female taking low-dose apixaban for atrial fibrillation and prior stroke came with acute right hemiparesis and aphasia of 150 min duration while undergoing ayurvedic treatment. Her National Institutes of Health Stroke Scale (NIHSS) score was 16 and blood pressure was 170/100 mmHg. The last dose of apixaban was taken 13 h before admission. Emergency computed tomography (CT) brain showed a hyperdense middle cerebral artery (MCA) sign with Alberta Stroke Program Early CT score of 7 [Figure 1a]. Her activated partial thromboplastin time and prothrombin time at the emergency was within normal range; thrombin time and anti-factor Xa activity assays were not available. She was given intravenous thrombolysis after discussing the risks with the available family member and caretaker. Tissue plasminogen activator was started by 200 min from onset with a door to needle time of 50 min. NIHSS score dropped 8 points in 2 h with improvement in motor scores. A repeat CT brain showed disappearance of the hyperdense MCA with a left frontotemporal infarct [Figure 1b]. The patient was started on aspirin after the 24 h CT scan which showed no evidence of bleeding. Mild word finding issues persisted. She was discharged after 5 days with low-dose apixaban which was later changed to full dose after a repeat CT taken at day 14. She was counseled well regarding the dose and schedule of apixaban and is under follow-up with no deficits.

As more patients are on newer oral anticoagulants (NOACs) for secondary prevention, identification of the right candidate for intravenous thrombolysis can be a challenge. Although guidelines suggest mechanical thrombectomy as the primary treatment and do not warrant intravenous thrombolysis for patients on NOACs, inadequate endovascular facilities make intravenous thrombolysis relevant. The emergency facilities to do anti-factor Xa activity, thrombin time, or ecarin clotting time are not available in most of the centers. Routine coagulation tests will not predict the accurate biological activity of the NOACs. However, a normal baseline coagulation profile can rule out a major overdosage. Of the NOACs, apixaban has a bleeding risk comparable to aspirin. Animal studies in rats showed less hemorrhagic transformation of infarct in rivaroxaban or apixaban pretreated rats compared to warfarin pretreated rats due to the reduced matrix metalloproteinase (MMP-9) expression by the anti-factor Xa inhibitors. Another multicenter observational cohort study reported that the patients on NOACs who underwent revascularization with intravenous thrombolysis for an acute ischemic stroke have a safety profile compared to when used in patients on subtherapeutic Vitamin K antagonist treatment or in those not on any anticoagulation. This case adds to this point that apixaban-treated patients can also be candidates for thrombolysis. A subgroup of patients with low drug levels could be eligible for thrombolysis, but identifying these patients at the emergency setting is difficult. A point of care device for the detection of three NOACs in emergency was feasible in a recent study. Many patients might have missed a single dose and could be exposed to risk of stroke. Significant drug or food interaction of factor Xa inhibitors due to intestinal P glycoprotein (P-gp) inhibition while taking ayurvedic medications containing phytates and...
other plant extracts could be a possible cause of poor drug levels and thrombus formation. Adequate awareness of this possible interaction should be emphasized to the patient during the anticoagulation counseling. Implementation of point of care device detecting anti-factor Xa will be an optimum step to plan intravenous thrombolysis as large number of patients will be on NOACs in the coming future.

Financial support and sponsorship
Nil.

Conflicts of interest
There are no conflicts of interest.

Vivek K. Nambiar, T. S. Dhanya, Amrutha V. Ajai
Division of Stroke, Centre of Neurosciences, Amrita Institute Medical Sciences, Kochi, Kerala, India

Address for correspondence: Dr. Vivek K. Nambiar, Division of Stroke, Centre of Neurosciences, Amrita Institute Medical Sciences, Ponekkara, Kochi - 682 041, Kerala, India. E-mail: dr.vivek.in@gmail.com

REFERENCES
1. Ikeda K, Tachibana H. Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation. J Arrhythm 2016;32:42-50.
2. Connolly SJ, Eikelboom J, Joyner C, Diener HC, Hart R, Golitsyn S, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17.
3. Kono S, Yamashita T, Deguchi K, Omote Y, Yunoki T, Sato K, et al. Rivaroxaban and apixaban reduce hemorrhagic transformation after thrombolysis by protection of neurovascular unit in rat. Stroke 2014;45:2404-10.
4. Seiffge DJ, Hooft RJ, Nolte CH, Béjot Y, Turc G, Ikenberg B, et al. Recanalization therapies in acute ischemic stroke patients: Impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome. Circulation 2015;132:1261-9.
5. Harenberg J, Du S, Wehling M, Zolfaghari S, Weiss C, Krämer R, et al. Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study. Clin Chem Lab Med 2016;54:275-83.
6. Stöllberger C, Finsterer J. Relevance of P-glycoprotein in stroke prevention with dabigatran, rivaroxaban, and apixaban. Herz 2015;40 Suppl 2:140-5.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Access this article online

Quick Response Code:  
Website:  
DOI: 10.4103/aian.AIAN_422_16

How to cite this article: Nambiar VK, Dhanya TS, Ajai AV. Successful revascularization of acute middle cerebral artery occlusion by intravenous thrombolysis while on apixaban. Ann Indian Acad Neurol 2017;20:161-2. 
© 2006 - 2017 Annals of Indian Academy of Neurology | Published by Wolters Kluwer - Medknow